Verona Pharma Plc ADR (VRNA) receives an Overweight rating from Wells Fargo
Verona Pharma Plc ADR’s recent filing unveils that its Director EBSWORTH DAVID R acquired Company’s shares for reported $0.19 million
Verona Pharma Plc ADR’s recent filing unveils that its Director EBSWORTH DAVID R acquired Company’s shares for reported $0.19 million
Investors can expect a company’s stock to rise or fall based on the buying and selling of stock by its
In a filing, Verona Pharma Plc ADR revealed its Chief Financial Officer Hahn Mark W unloaded Company’s shares for reported
Investors can expect a company’s stock to rise or fall based on the buying and selling of stock by its
In a filing, Verona Pharma Plc ADR revealed its Chief Financial Officer Hahn Mark W unloaded Company’s shares for reported
The buying and selling of stock by a company’s insider give investors a sense that the stock will rise or
Verona Pharma Plc ADR’s recently made public that its Officer MARK HAHN acquired Company’s shares for reported $3.47 million on
The buying and selling of stock by a company’s insider give investors a sense that the stock will rise or
Verona Pharma Plc ADR’s filing revealed that its President and CEO ZACCARDELLI DAVID unloaded Company’s shares for reported $2.25 million
Investors can expect a company’s stock to rise or fall based on the buying and selling of stock by its
This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.
Strictly Necessary Cookie should be enabled at all times so that we can save your preferences for cookie settings.
If you disable this cookie, we will not be able to save your preferences. This means that every time you visit this website you will need to enable or disable cookies again.